In the latest trading session,, 1.27 million Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares changed hands as the company’s beta touched 0.68. With the company’s most recent per share price at $19.56 changed hands at -$0.02 or -0.10% at last look, the market valuation stands at $2.46B. APLS’s current price is a discount, trading about -123.72% off its 52-week high of $43.76. The share price had its 52-week low at $16.10, which suggests the last value was 17.69% up since then.
Analysts gave the Apellis Pharmaceuticals Inc (APLS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.87. If we narrow down to specifics, the data shows that 0 out of 14 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 2 recommended APLS as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight. Apellis Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.46.
Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information
Instantly APLS was in red as seen in intraday trades today. With action 5.67%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -38.70%, with the 5-day performance at 5.67% in the green. However, in the 30-day time frame, Apellis Pharmaceuticals Inc (NASDAQ:APLS) is 11.64% up.
The consensus price target for the stock as assigned by Wall Street analysts is 76, meaning bulls need an upside of 74.26% from its recent market value. According to analyst projections, APLS’s forecast low is 39 with 113 as the target high. To hit the forecast high, the stock’s price needs a -477.71% plunge from its current level, while the stock would need to soar -99.39% for it to hit the projected low.
Apellis Pharmaceuticals Inc (APLS) estimates and forecasts
Year-over-year growth is forecast to reach -0.92% down from the last financial year.
Consensus estimates given by 18 financial analysts project the company’s revenue in the current quarter to hit an average of 187.9M. 18 analysts are of the opinion that Apellis Pharmaceuticals Inc’s revenue for the current quarter will be 203.36M. The company’s revenue for the corresponding quarters a year ago was 199.69M and 196.83M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -5.90%. The estimates for the next quarter sales put growth at 3.32%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 20.08%. The 2025 estimates are for Apellis Pharmaceuticals Inc earnings to decrease by -21.78%.
APLS Dividends
Apellis Pharmaceuticals Inc is expected to release its next quarterly earnings report in July.
ECOR1 CAPITAL, LLC holds the second largest percentage of outstanding shares, with 9.3681% or 11.61 million shares worth $445.26 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 8.48 shares estimated at $165.73 million under it, the former controlled 6.75% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.66% of the shares, roughly 3.34 shares worth around $65.24 million.
